Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 15/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 14/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6283958 | 0.99 | PDGFRB (0.68) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL8499898 | 0.86 | PDGFRB (0.52) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL8562767 | 0.85 | PDGFRB (0.51) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL8171746 | 0.83 | PDGFRB (0.61) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL8172666 | 0.82 | PDGFRB (1.00) | PDGFRBPDGFRA | |
| SCHEMBL8500249 | 0.82 | PDGFRB (0.61) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL29351353 | 0.78 | SMN1; SMN2 (1.00) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL595944 | 0.78 | SMN1; SMN2 (1.00) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL8502224 | 0.77 | ALDH1A1 (0.74) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL8500142 | 0.77 | SMN1; SMN2 (0.97) | PDGFRBPDGFRAALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411034-B1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2017-07-26 | — | — | EP | claimed |
| US-20060058307-A1 | Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-16 | — | — | US | claimed |
| US-6974816-B2 | Combination for the treatment of endothelial damage | LICENTIA LTD. (FI) | 2005-12-13 | — | — | US | claimed |
| EP-1441717-A1 | COMBINATION OF AN ATP-COMPETITIVE INHIBITOR OF BCR/ABL KINASE ACTIVITY AND A TYRPHOSTIN ANALOG | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030099687-A1 | Combination for the treatment of endothelial damage | LICENTIA LTD. (FI) | 2003-05-29 | — | — | US | claimed |
| WO-2003037322-A1 | COMBINATION OF AN ATP-COMPETITIVE INHIBITOR OF BCR/ABL KINASE ACTIVITY AND A TYRPHOSTIN ANALOG | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-05-08 | — | — | WO | claimed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | claimed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | claimed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | claimed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | claimed |
| US-9844572-B2 | Promotion of neuronal integration in neural stem cell grafts | LIFE & BRAIN GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| EP-2411034-B1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20120093832-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20030099687-A1 | Combination for the treatment of endothelial damage | LICENTIA LTD. (FI) | 2003-05-29 | — | — | US | disclosed |
| WO-2003037322-A1 | COMBINATION OF AN ATP-COMPETITIVE INHIBITOR OF BCR/ABL KINASE ACTIVITY AND A TYRPHOSTIN ANALOG | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-05-08 | — | — | WO | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058307-A1 | Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog | ABL1, ABL2, BTK | PDGFRB 91/4885PDGFRA 94/4885ALDH1A1 3011/4885 |
| US-20120093832-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | DCX, NGF, BDNF | PDGFRB 321/4885PDGFRA 516/4885ALDH1A1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.